rana Ghaleb

Dr. rana Ghaleb

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Medical Journal of Babylon
Verified
Journal Article
Open access
SOSarah K Obayes
Sarah K Obayes
SESabah H Enayah
Sabah H Enayah
SAShaimaa A Al-Oubaidy
Shaimaa A Al-Oubaidy
RGrana Ghaleb
rana Ghaleb
Background: MicroRNA (miRNA) is a short, single-stranded, non-coding sequence of RNA that does not translate into proteins. Because of their ability to control gene expression, recent studies have shown that these short, non-coding sequences play an important role in cancer. So that, detection the polymorphisms or variants in miRNA genes may help to identify their correlation to cancer susceptibility. Objectives: Study the polymorphisms in miRNA genes or variants miRNA genes and their correlation with myeloma disease. Materials and Methods: Twenty samples were collected from people who visited Marjan Hospital in Province of Babylon, Iraq, from February to July 2022. In addition, 20 samples from healthy people were collected as control. Genotyping of miRNA was accomplished using the polymorphism techniques of polymerase chain reaction and single strand conformation polymorphism (SSCP). DNA sequencing was also applied to categorize all the ranges of SSCP models detected using only gel imaging. Results: The genotypes obtained in this experiment verified that several single nucleotide polymorphisms were obtained between 5-band and 6-band miRNA National center for biotechnology information Primer3 plus reference. Conclusion: The results explain that the miRNA gene polymorphisms may have correlation with the susceptibility to myeloma disease.

6 June 2023 in Maaen Journal for Medical Sciences
Verified
Journal Article
Open access
PDF file
AWAli Wannas
Ali Wannas
SOSarah K. Obayes
Sarah K. Obayes
ZSZahraa Fathi Sharba
Zahraa Fathi Sharba
RGrana Ghaleb
rana Ghaleb
Lipid nanoparticles (LNP) are the most well-studied first approved nanomedicine for drug delivery of therapeutic and vaccine formulation products. However, their nature is under constant investigation especially their liquid crystal state which leads to their complex biological behavior. LNPs are generally regarded as safe (GRAS) and suitable for ameliorating the toxicity and/or improving the pharmacokinetics of newly approved biomaterials with promising functionality and effects. During the past decade, many promising theranostic applications for LNPs have emerged resulting in huge potential for them in this field. Although there is progress in theranostic application, the gap between the bench and clinical application is undeniable, and that must be addressed to exploit the benefits of these nanomedicines for society.

1 April 2025 in Medical Journal of Babylon
Verified
Journal Article
Open access
AAAli M. Jaafar Abdulsahib
Ali M. Jaafar Abdulsahib
RGrana Ghaleb
rana Ghaleb
NMNisreen Jalal Mohammed
Nisreen Jalal Mohammed
Background: Colorectal cancers are the 3rd highest commonly discovered form of cancer worldwide. The outcomes of various studies have revealed that cancer cells growth has been affected in response to treatment. In this study, the in vitro cytotoxic effects of different drug combinations [5-fluorouracil (5-FU), curcumin, and febuxostat] were measured by crystal violet method. The results showed significant anticancer activity on LS174T colorectal cancer cell line at different combinations. Objective: This study aimed to assess the cytotoxic effect of different combinations of 5-FU, curcumin, and febuxostat on colorectal cancer LS174 cell line. Materials and Methods: For 24 h, the human colon cancer cell line LS174T was given a variety of doses of combinations of 5-FU, febuxostat, and curcumin. Crystal violet assay was used to assess the cytotoxicity of the combined agents extract against colon cancer cells. Results: 5-FU, curcumin, and febuxostat when used in different combinations concentrations, showed respectable anticancer effect on colorectal cancer LS174T cell line. Conclusion: The current study indicated that the good anticancer effects of combined agents when used to treat colorectal cancer.